By offering unproven therapies, a Texas biotechnology firm has sparked a bitter debate about how stem cells should be regulated.
This is a preview of subscription content, log in via an institution to check access.
References
Caplan, A. I. & Correa, D. Cell Stem Cell 9, 11–15 (2011).
von Bahr, L. et al. Stem Cells 30, 1575–1578 (2012).
Alderazi, Y. J. et al. J. Child Neurol. 27, 632–635 (2012).
Lalu, M. M. et al. PLoS ONE 7, e47559 (2012).
Connick, P. et al. Lancet Neurol. 11, 150–156 (2012).
Additional information
See Editorial page 147
Related links
Related links
Related links in Nature Research
Preventive therapy 2013-Feb-13
Controversial stem-cell company moves treatment out of the United States 2013-Jan-30
Korea okays stem cell therapies despite limited peer-reviewed data 2012-Mar-06
Controversial bioethicist quits stem-cell company 2012-Mar-01
Stem-cell therapy takes off in Texas 2012-Feb-29
Texas prepares to fight for stem cells 2011-Sep-20
Stem-cell scientists grapple with clinics 2011-Jun-28
Korean deaths spark inquiry 2010-Nov-23
Blogpost: Texas stem-cell provider under FDA gun
Blogpost: US drug regulator audits Texas stem-cell company
Related external links
Rights and permissions
About this article
Cite this article
Cyranoski, D. Stem cells in Texas: Cowboy culture. Nature 494, 166–168 (2013). https://doi.org/10.1038/494166a
Published:
Issue Date:
DOI: https://doi.org/10.1038/494166a
- Springer Nature Limited
This article is cited by
-
Regenerative Cell-Based Therapies: Cutting Edge, Bleeding Edge, and Off the Edge
Regenerative Engineering and Translational Medicine (2020)
-
The malignant niche: safe spaces for toxic stem cell marketing
npj Regenerative Medicine (2017)
-
Regulated and Unregulated Clinical Trials of Stem Cell Therapies for Stroke
Translational Stroke Research (2017)
-
Mesenchymal stem cell treatments in rheumatology—a glass half full?
Nature Reviews Rheumatology (2014)